Pricing Log in Create free account

Arvinas, Inc. (ARVN) vs Eupraxia Pharmaceuticals Inc. (EPRX)

Arvinas, Inc. and Eupraxia Pharmaceuticals Inc. are both Biotechnology companies. Arvinas, Inc. and Eupraxia Pharmaceuticals Inc. are of similar size ($429.1M and $428.9M). Eupraxia Pharmaceuticals Inc. has the higher net margin (0.00% vs −3.45%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Arvinas, Inc. leads on 6 and Eupraxia Pharmaceuticals Inc. on 6.

Valuation

Metric ARVN EPRX Biotechnology median
P/E n/m n/m 10.60
P/S 1.52 n/m 9.40
P/B 0.81 4.52 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 4.29 n/m 0.66
EV/Sales (0.51) n/m 9.02
Earnings yield (2.39%) (14.46%) (32.88%)
Free cash flow yield (38.24%) (8.45%) (23.13%)

Profitability

Metric ARVN EPRX Biotechnology median
Gross margin 96.69% — 68.51%
Operating margin (12.13%) 0.00% 0.00%
Net margin (3.45%) 0.00% 0.00%
Free cash flow margin (58.05%) 0.00% 0.00%
Return on equity (1.76%) (117.82%) (51.96%)
Return on assets (1.31%) (64.44%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN EPRX Biotechnology median
Revenue growth (TTM) (11.85%) — 6.76%
EPS growth (last fiscal year) 58.84% (35.53%) 29.88%
Revenue growth, 5-year CAGR 58.93% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ARVN EPRX Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 8.39 16.00 4.97
Net debt to EBITDA 5.62 2.11 1.01

Dividend

Metric ARVN EPRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARVN EPRX Biotechnology median
Market cap 428.93m 429.13m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack